Stock Events

Stock Events

Forte Biosciences 

$36.70
15
+$16.12+78.33% Thursday 19:59
+$1.70+4.63%Thursday 23:59After hours

Statistics

Day High
37.07
Day Low
36.66
52W High
37.58
52W Low
9.1
Volume
71,889
Avg. Volume
-
Mkt Cap
751.57M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-6.75
-4.82
-2.88
-0.95
Expected EPS
-1.03
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-69.38MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FBRX. It's not an investment recommendation.
Tesla
3
TSLA
NVIDIA
3
NVDA
Eos Energy Enterprises
3
EOSE
Quantum Computing
3
QUBT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals competes in the development of biologic drugs for skin diseases, similar to Forte Biosciences' focus on dermatology.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie has a strong portfolio in dermatology, including treatments for conditions that Forte Biosciences targets.
AMGEN
AMGN
Mkt Cap201.93B
Amgen has a presence in the dermatology market, competing with Forte Biosciences in developing treatments for skin conditions.
Journey Medical
DERM
Mkt Cap195.22M
Journey Medical Corporation (formerly Dermira) focuses on dermatological conditions, directly competing with Forte Biosciences' dermatology focus.
AnaptysBio
ANAB
Mkt Cap1.88B
AnaptysBio is involved in developing therapeutic antibodies for inflammatory diseases, including dermatological conditions, making it a competitor.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences, through its acquisition of Immunomedics, competes in the biopharmaceutical space with a focus on treatments that could overlap with Forte Biosciences' interests.
Merck
MRK
Mkt Cap319.99B
Merck & Co. has a diversified portfolio that includes treatments for skin diseases, competing with Forte Biosciences in the dermatology space.
Pfizer
PFE
Mkt Cap138.61B
Pfizer has a broad range of healthcare products, including those for dermatological conditions, making it a competitor to Forte Biosciences.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, offers products for dermatology, competing with Forte Biosciences.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol Myers Squibb has a diverse biopharmaceutical portfolio that includes treatments for skin diseases, competing with Forte Biosciences.

About

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Show more...
CEO
Dr. Paul A. Wagner Ph.D.
Employees
14
Country
United States
ISIN
US34962G2084

Listings

STU
DE
37T.STU
MU
DE
37T.MU
BOATS
BOATS
FBRX.BOATS
F
DE
37T.F

0 Comments

Share your thoughts

FAQ

What is Forte Biosciences stock price today?▼
The current price of FBRX is $36.70 USD — it has increased by +78.33% in the past 24 hours. Watch Forte Biosciences stock price performance more closely on the chart.
What is Forte Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Forte Biosciences stocks are traded under the ticker FBRX.
Is Forte Biosciences stock price growing?▼
FBRX stock has risen by +75.43% compared to the previous week, the month change is a +118.19% rise, over the last year Forte Biosciences has showed a +220.38% increase.
What is Forte Biosciences market cap?▼
Today Forte Biosciences has the market capitalization of 751.57M
When is the next Forte Biosciences earnings date?▼
Forte Biosciences is going to release the next earnings report on August 17, 2026.
What were Forte Biosciences earnings last quarter?▼
FBRX earnings for the last quarter are -1.24 USD per share, whereas the estimation was -1.16 USD resulting in a -6.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Forte Biosciences revenue for the last year?▼
Forte Biosciences revenue for the last year amounts to 0 USD.
What is Forte Biosciences net income for the last year?▼
FBRX net income for the last year is -69.38M USD.
How many employees does Forte Biosciences have?▼
As of July 10, 2026, the company has 14 employees.
In which sector is Forte Biosciences located?▼
Forte Biosciences operates in the Health & Wellness sector.
When did Forte Biosciences complete a stock split?▼
The last stock split for Forte Biosciences was on August 28, 2024 with a ratio of 1:25.
Where is Forte Biosciences headquartered?▼
Forte Biosciences is headquartered in Dallas, United States.